Cardiovascular Diseases
Conditions
Brief summary
The primary aim of the proposed investigation is to examine the hypothesis that a relatively short period of rhamnan sulfate supplementation would improve key markers of vascular dysfunction in middle-aged and older adults with at least one risk factors for cardiovascular disease.
Interventions
DIETARY_SUPPLEMENTRhamnan sulfate
A randomized, placebo-controlled, double-blind crossover dietary supplement intervention consisting of 3 weeks each of rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) or placebo with 2 weeks of washout between the interventions will be conducted. Dietary supplements (rhamnan sulfate) will be taken orally three time daily at each meal time. Rhamnan sulfate is a polysaccharide (carbohydrate) extracted from seaweeds and can be considered nutrition supplement. As each pill contains 90 mg of rhamnan sulfate or placebo, subjects will be taking 2 pills before or during each meal.
Sponsors
University of Texas at Austin
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
35 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* at least one risk factor for cardiovascular disease (e.g., dyslipidemia, hypertension, obesity, impaired fasting glucose) * a BMI of \<40 kg/m2
Exclusion criteria
* gastrointestinal disorders and/or renal disease * pregnancy or lactation * strenuous physical activity (\>3 times/week) * alcohol abuse
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vascular function | Before the 3-week intervention | Endothelium-dependent vasodilation as assessed by flow-mediated dilation |
Countries
United States
Outcome results
None listed